Penserra Capital Management LLC Invests $472,000 in Moderna, Inc. $MRNA

Penserra Capital Management LLC acquired a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) during the third quarter, HoldingsChannel.com reports. The institutional investor acquired 18,291 shares of the company’s stock, valued at approximately $472,000.

Other institutional investors have also added to or reduced their stakes in the company. Rothschild Investment LLC grew its holdings in Moderna by 94.1% during the 2nd quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock valued at $25,000 after buying an additional 446 shares in the last quarter. Atlantic Union Bankshares Corp bought a new position in shares of Moderna in the second quarter valued at approximately $26,000. Whittier Trust Co. purchased a new position in Moderna during the second quarter valued at approximately $28,000. MUFG Securities EMEA plc bought a new stake in Moderna during the 2nd quarter worth approximately $28,000. Finally, Assetmark Inc. lifted its stake in Moderna by 137.7% in the 2nd quarter. Assetmark Inc. now owns 1,298 shares of the company’s stock worth $36,000 after purchasing an additional 752 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Stock Up 0.3%

Shares of NASDAQ MRNA opened at $41.01 on Monday. The firm’s fifty day moving average is $35.65 and its 200 day moving average is $29.55. Moderna, Inc. has a 52 week low of $22.28 and a 52 week high of $55.20. The company has a market cap of $16.02 billion, a price-to-earnings ratio of -5.08 and a beta of 1.32.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.15) by $1.64. Moderna had a negative net margin of 139.61% and a negative return on equity of 29.81%. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $893.29 million. During the same quarter last year, the firm earned $0.03 EPS. The company’s revenue was down 45.4% on a year-over-year basis. Equities research analysts anticipate that Moderna, Inc. will post -9.61 earnings per share for the current year.

Insider Buying and Selling at Moderna

In related news, Director Noubar Afeyan sold 23,853 shares of the firm’s stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $29.48, for a total value of $703,186.44. Following the sale, the director directly owned 3,924 shares of the company’s stock, valued at $115,679.52. This trade represents a 85.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 10.90% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on the company. Citigroup reaffirmed a “neutral” rating on shares of Moderna in a report on Monday, January 19th. Leerink Partners restated an “underperform” rating on shares of Moderna in a report on Friday, January 30th. TD Cowen reaffirmed a “hold” rating on shares of Moderna in a research note on Thursday, January 29th. Wolfe Research reiterated an “underperform” rating and issued a $17.00 target price on shares of Moderna in a research report on Thursday, November 20th. Finally, Royal Bank Of Canada reissued a “sector perform” rating on shares of Moderna in a research note on Monday, January 12th. Two research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and five have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Reduce” and an average target price of $28.77.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.